Accepted at 12:58 a.m. Dec, 29, 2023 by Cameron
Author: evbalk
Related Note: 1484950422509
Rationale for change

Looks like earlier discussion on inverse agonist vs antagonist has been cleared up. Comment no longer needed.

Sketchy Sketchy
Text
{{c1::Naloxone}} is a μ-opioid antagonist used to treat acute opioid toxicity (can precipitate withdrawal)
Extra
Naltrexone on the other hand helps maintain abstinence in opioid use disorder once detoxified
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize



Physeo



Bootcamp
Watch associated Bootcamp video - Opioids

Watch associated Bootcamp video - Opioid Classification

Watch associated Bootcamp video - Side Effects and Toxins: Pharmacological Toxicity and Treatment
OME

Additional Resources
Empty field
One by one
Empty field
#AK_Step2_v12::#AMBOSS::DH01sh #AK_Step2_v12::#UWorld::Step::105921 !AK_UpdateTags::Step1decks::Zanki-Pharmacology #PANCE::EOR::PSYCH #AK_Step2_v12::#B&B::13_Psychiatry::03_Substance_Abuse::02_Substance_Abuse_I #AK_Step1_v12::#UWorld::Step::16502 #AK_Step2_v12::#AMBOSS::ZCaZq5 #AK_Step1_v12::#FirstAid::13_Psychiatry::03_Pharm::14_Opioid_Detoxification_&_Relapse_Prevention::Naloxone #AK_Step2_v12::#UWorld::Step::12503 #AK_Step1_v12::^Other::^HighYield::1-HighYield #AK_Step1_v12::#AMBOSS::FOag8k #AK_Step2_v12::#UWorld::COMLEX::106686 #AK_Step1_v12::#B&B::15_Neuro::06_Anesthesia::01_General_Anesthesia #AK_Step1_v12::#Physeo::09_Pharm::13_Psychiatric::30_Opioid_Withdrawal,_Detoxification_and_Relapse_Prevention #AK_Step2_v12::#UWorld::#UWSA1 #AK_Step1_v12::#AMBOSS::vaaAmQ #AK_Step1_v12::#SketchyPharm::06_Neuro_&_Psych::01_Anesthetics_&_Analgesics::03_Opiates,_Naloxone,_Naltrexone #AK_Step1_v12::#FirstAid::05_Pharmacology::03_Toxicities_&_Side_Effects::01_Specific_toxicity_treatments #AK_Step1_v12::#Pixorize::03_Pharmacology::16_Other_Neuro_Pharm::17_Full_Opioid_Agonists #AK_Step2_v12::#SketchyPsych::10_Substance_Use/_Medication_Related_Disorders::01_Substance_Use_Overview #AK_Step1_v12::#B&B::17_Psych::03_Substance_Use::02_Opioids #AK_Step1_v12::#FirstAid::13_Psychiatry::03_Pharm::14_Opioid_Detoxification_&_Relapse_Prevention #AK_Step1_v12::#UWorld::COMLEX::26550 #AK_Step2_v12::#UWorld::Step::6889 #AK_Step1_v12::^Systems::Neuro::Pharmacology #AK_Step1_v12::#Bootcamp::Pharmacology::04_Side_Effects_and_Toxins::02_Pharmacological_Toxicity_and_Treatment #AK_Step1_v12::#UWorld::Step::16052 #AK_Step1_v12::#UWorld::Step::1256 #AK_Step1_v12::#Pixorize::^Missing_image #AK_Step1_v12::$AnKingUpdates::USMLE #AK_Step1_v12::#Pixorize::03_Pharmacology::16_Other_Neuro_Pharm::21_Naloxone #AK_Step1_v12::#Bootcamp::Pharmacology::01_Pharmacodynamics::09_Drug-Receptor_Interactions #AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step1_v12::#OME::PreClinical::Neuroscience::Neuroscience_4::Clinical_Cortex::Anesthesia #AK_Step1_v12::#Physeo::^physeo_image_update #PANCE::BEHAVIORAL::substance_use #PANCE::EOR::Family_med #AK_Step1_v12::#Bootcamp::Psychiatry::08_Substance_Misuse::03_Opioids #AK_Step1_v12::#Physeo::09_Pharm::14_Neuro::21_Opioid_Clinical_Use,_Mechanism_and_Overdose #AK_Step2_v12::#UWorld::COMLEX::102301 #AK_Step1_v12::#UWorld::COMLEX::24367 #AK_Step3_v12::#UWorld::5193 #AK_Step1_v12::#Bootcamp::Psychiatry::08_Substance_Misuse::04_Opioid_Classification